SBRT has equivalent toxicity with 5 treatments and 12 treatments: an update

We first reported data from the results of the RTOG 0938 trial in January 2016 when they were presented at the Genitourinary Cancers Symposium in that year. These results have now been formally published, and there are some changes to the data on publication, so Allen Edel has provided an update. … READ MORE …

First randomized clinical trial of SBRT reports primary outcome

In the first trial ever to randomly assign patients to extreme hypofractionation, primary radiation therapy delivered in just seven treatments had the same effectiveness and safety as 39 treatments. … READ MORE …

Salvage SBRT after radical prostatectomy

The University of California, Los Angeles (UCLA) has announced a new clinical trial using stereotactic body radiation therapy (SBRT) for treatment of recurrent prostate cancer after failure of initial prostatectomy. … READ MORE …

Record 10-year SBRT study among low-risk patients

Alan Katz has now published the study with the longest-running follow-up of any study of external beam radiation therapy for prostate cancer among low-risk patients, in this case using SBRT. … READ MORE …

First US randomized clinical trial of oligometastasis-directed SBRT

In a recent commentary (see this link), we saw that some clinicians are making unsubstantiated claims of cancer control from treatment of oligometastases (less than 5 detected metastases). … READ MORE …

Life, behavior, and prostate cancer risk: should you be shedding a few pounds?

The capacity of the average male human to do things that are probably not very good for his health (and to not do things that probably would be good for his health) is considerable. At the most basic level, for example, most of us here in the US don’t eat very wisely and don’t take anything like enough exercise. … READ MORE …

Safety limits of SBRT dose escalation

In a recent commentary, we saw that the lack of a standard of care for stereotactic body radiation therapy (SBRT) dose escalation may put patients at risk when dose limits are pushed beyond what is customarily considered effective and safe. … READ MORE …